ACC.24 Scientific Sessions 2024
VICTORION-INITIATE supports early inclisiran treatment in ASCVD
Starting inclisiran as soon as patients with atherosclerotic cardiovascular disease (ASCVD) fail to reach LDL-C target leads to greater LDL-C lowering than next step usual care, without discouraging statin use or raising new safety concerns. This is the main conclusion from the VICTORION-INITIATE – a…
read more »
LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD
Lerodalcibep, the small recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin (HSA), reduced LDL-C by 56% compared to placebo (p<0.0001) at week 52 in the LIBerate-HR trial, including in patients at high and very high risk of cardiovascular disease (CVD).1 In…
read more »
US patients missing out on bempedoic acid
Nearly half of US patients prescribed bempedoic acid may have been missing out on treatment due to payer rejections and prescription abandonment, according to an analysis of national pharmacy transaction data from 2020, when the drug was approved as a lipid lowering agent, through to…
read more »
Evolocumab benefits in patients with autoimmune and inflammatory diseases
Evolocumab appears to have greater clinical benefits in patients with atherosclerotic cardiovascular disease (ASCVD) and autoimmune or chronic inflammatory diseases (AIID) than those without these comorbidities. An analysis of 889/27,564 (3.2%) of patients in the FOURIER trial who had an AIID has shown a trend…
read more »
